Summary
Breast cancer treatment centres on three factors: the stage, the tumour's receptor status (ER, PR, and HER2), and your overall health. Most people receive a combination of surgery, radiation, and drug treatment, which can include chemotherapy, hormone therapy, and targeted therapy. HER2-positive breast cancer, which makes up roughly 15 to 20% of cases, responds well to HER2-targeted drugs like trastuzumab, and cheaper Indian biosimilars have made these far more accessible.
Costs in India range from a few lakh rupees for early-stage disease to well over ₹10 lakh for locally advanced cases. The earlier it's caught, the simpler and cheaper treatment usually is.
Breast Cancer Treatment in India: Options, Costs and What to Expect
How breast cancer is treated, what HER2-positive disease means, and what each step costs
This page is for informational purposes only and does not replace medical advice. Please consult Dr Aditya Sarin or a qualified oncologist about your specific diagnosis and plan. Costs vary by hospital and change often, so confirm figures with your care team. As of 2026, this reflects current clinical guidance.
A breast cancer diagnosis comes with a lot of decisions at once: surgery or not, chemo or not, what the receptor results mean, and what it will all cost. This guide walks through the standard options, how doctors choose between them, and what to expect in India, so you can go into those conversations better prepared.
Breast cancer in India: Why timing matters
Breast cancer is the most common cancer among women in India. According to GLOBOCAN 2022 figures cited in JCO Global Oncology, India recorded about 192,020 new cases and 98,337 deaths that year. The same review points to late-stage presentation and limited access to diagnostics as ongoing problems.
Age and stage matter. A review in the World Journal of Clinical Oncology notes that a higher proportion of breast cancer occurs at a younger age in Indian women than in the West, and links poorer survival partly to late presentation and delayed treatment. Hospital series from India have reported a notably higher share of stage IV disease at diagnosis than in the US. The practical lesson: a new lump, nipple discharge, skin dimpling, or persistent armpit swelling deserves a prompt clinical examination, not a wait-and-see approach.
How is breast cancer treatment decided?
Stage and grade
Stage describes the tumour’s size and whether it has spread to lymph nodes or other organs. Grade describes how abnormal the cells look.
Receptor status: The three main subtypes
The biopsy is tested for estrogen receptor (ER), progesterone receptor (PR), and HER2. These results sort breast cancers into groups that behave and respond differently:
- Hormone receptor-positive: fuelled by estrogen or progesterone, so hormone-blocking treatment works
- HER2-positive: carries extra HER2 protein, so HER2-targeted drugs work
- Triple-negative: lacks all three, so chemotherapy (and sometimes immunotherapy) carries more of the load
Cancer Australia notes that chemotherapy is more likely when the cancer has no hormone receptors, and that HER2 status can change which chemotherapy is used and when.
Breast cancer surgery in India
Surgery is usually part of early-stage treatment. Cancer Australia describes the two main approaches as breast-conserving surgery and mastectomy, with reconstruction possible after mastectomy.
Lumpectomy vs mastectomy
A lumpectomy removes the tumour and a margin of surrounding tissue. A mastectomy removes the whole breast. For early-stage cancer, lumpectomy followed by radiation is generally considered as effective as mastectomy at preventing recurrence, according to Care Hospitals. The right choice depends on tumour size, location, how many areas are involved, genetic risk, and your preference. Neither is automatically “safer.”
Lymph node surgery
Surgeons usually check the lymph nodes under the arm, often with a sentinel node biopsy that identifies the first nodes cancer would reach. The results help stage the cancer and guide whether more treatment is needed.
Breast reconstruction
Reconstruction can be done at the same time as a mastectomy or later, using implants or your own tissue. It’s optional, and it’s worth raising early, because the plan for surgery and radiation affects the options.
Radiation therapy
Radiation is almost always recommended after breast-conserving surgery, and sometimes after mastectomy, to destroy remaining cancer cells. It’s delivered by a radiation oncologist as a course over several weeks. If you’d like a clearer picture of that role, see our guide to radiation vs medical oncologists.
Breast cancer chemotherapy
Chemotherapy kills fast-dividing cells throughout the body, and it’s used when there’s a meaningful risk that cancer cells have spread beyond the breast and armpit.
Before or after surgery
CancerCare explains that chemotherapy can be given before surgery (neoadjuvant) to shrink the tumour so surgery can be less extensive, or after surgery (adjuvant) to destroy remaining cells. It’s particularly important in triple-negative disease. Side effects are real but manageable, and our chemotherapy side effects guide covers nausea, fatigue, hair loss, and when to call your team.
Hormone therapy
For ER- or PR-positive cancers, hormone therapy reduces estrogen’s effect on cancer cells. Tamoxifen is the best-known example, an estrogen-blocking treatment. The choice of drug depends on hormone receptors and whether you’ve reached menopause. You usually take it as a daily tablet for several years, so it’s worth discussing long-term side effects and how to stay on schedule upfront.
Targeted therapy for HER2-positive breast cancer
HER2-positive breast cancer used to carry a worse outlook. Targeted drugs changed that. Targeted therapy for breast cancer works by attacking cells with high levels of the HER2 protein, and it’s usually combined with chemotherapy.
The main HER2-targeted drugs
According to CancerCare:
- Trastuzumab (Herceptin) is a standard treatment, typically taken for one year in early-stage disease
- Pertuzumab (Perjeta) is added to trastuzumab and chemotherapy before surgery in some patients
- Ado-trastuzumab emtansine (T-DM1, Kadcyla) joins trastuzumab to a chemotherapy drug
- Neratinib (Nerlynx) can be given after a year of trastuzumab to further reduce recurrence in selected patients
Not everyone qualifies. HER2 status is determined by your pathology report, and these drugs work only on HER2-positive tumours.
Biosimilars have changed the cost picture in India
Trastuzumab biosimilars are among the biggest affordability wins in Indian oncology. A real-world analysis presented at ISPOR Europe 2025 found the originator at ₹55,000 to ₹75,000 per 440 mg vial in private pharmacies, versus ₹18,000 to ₹30,000 for biosimilars, a 50 to 70% reduction. Pertuzumab is catching up: Alkem launched a biosimilar in India in September 2025, according to BioSpectrum, which noted that cost had kept pertuzumab out of reach for many patients.
Triple-negative breast cancer and immunotherapy
Triple-negative breast cancer lacks the targets for hormone and HER2 therapy, so chemotherapy is the mainstay. For some high-risk early-stage cases, the US FDA approved pembrolizumab alongside chemotherapy in 2021. Whether it applies to you, and whether it’s accessible, is a conversation for your oncologist.
Breast cancer treatment cost in India
Costs vary by stage, subtype, hospital, and drugs, so treat these as rough ranges, not quotes. Published figures differ between sources.
Cost by stage
Stage | Typical treatment | Indicative total cost |
Stage I | Lumpectomy or localised surgery, often with radiation | About ₹2 to 4 lakh |
Stage II | Surgery, chemotherapy, radiation | About ₹5 to 8 lakh |
Stage III | More extensive surgery, multiple chemotherapy cycles, targeted therapy | About ₹8 to 15 lakh |
Stage IV | Depends on drugs and duration of treatment | Varies widely |
Source: HCG Oncology, which also puts breast cancer surgery alone at roughly ₹1.5 to 5 lakh depending on whether it’s a lumpectomy, mastectomy, or includes reconstruction.
What HER2 treatment adds
A full course of trastuzumab runs about 18 cycles. When biosimilars launched in 2019, Intas estimated that this dropped from more than ₹10 lakh to under ₹4 lakh (GaBI Online). Prices have fallen further since, but a total plan with pertuzumab or T-DM1 costs significantly more.
Ways to pay
Ayushman Bharat PM-JAY covers cancer treatment for eligible families up to ₹5 lakh a year, and Delhi joined the scheme in 2025, as covered in our guide to cancer treatment in India. Ask whether your specific drugs are covered, and check private insurance sub-limits too.
What to expect during treatment
A typical early-stage path looks something like this, though yours will be tailored:
- Diagnosis and staging: biopsy, receptor tests, and imaging
- Surgery (or chemotherapy first, if the plan starts with shrinking the tumour)
- Chemotherapy and/or targeted therapy, usually over several months
- Radiation, often after surgery
- Hormone therapy, if hormone receptor-positive, for years
- Follow-up, with regular check-ups and imaging
Treatment is a long road, and it’s normal to need support along the way. Ask your team early about nutrition, fertility preservation (if you’re younger), and emotional support.
The takeaway
Breast cancer is highly treatable, particularly when found early, and the right plan depends on your stage and receptor status rather than on one-size-fits-all steps. If you’ve been diagnosed, a medical oncologist can help coordinate surgery, systemic therapy, and radiation into one plan. To discuss your own case, book a consultation with Dr Aditya Sarin.
References
- JCO Global Oncology: Comprehensive Overview of Breast Cancer in India
- World Journal of Clinical Oncology: Breast Cancer in India, Present Scenario and the Challenges Ahead
- PMC: Triple-Negative Breast Cancer in India, Panel Discussion on Trends and Obstacles
- Cancer Australia: Early Breast Cancer Treatment
- Care Hospitals: Breast Lump Removal Surgery
- HCG Oncology: Affordable Breast Cancer Treatment Cost in India
- ISPOR Europe 2025: Impact of Trastuzumab Biosimilar Adoption in India
- GaBI Online: Intas Launches Trastuzumab Similar Biologic in India at 65% Discount
Frequently Asked Questions
What is HER2-positive breast cancer?
It’s breast cancer with extra HER2 protein on the surface of its cells, which can make it grow faster. It makes up roughly 15 to 20% of breast cancers and responds well to HER2-targeted drugs like trastuzumab.
Do I need a mastectomy or is a lumpectomy enough?
For many early-stage cancers, a lumpectomy followed by radiation works as well as mastectomy. The right choice depends on tumour size and location, genetics, and your preferences.
Will I need chemotherapy for breast cancer?
Not always. It depends on stage, receptor status, and the risk of spread. It’s more likely when the cancer is triple-negative or lymph nodes are involved.
How much does breast cancer treatment cost in India?
Early-stage treatment often runs from about ₹2 to 4 lakh, while locally advanced disease can cost ₹8 to 15 lakh or more. Targeted drugs and hospital type affect the total.
Are cheaper trastuzumab biosimilars as good as the original?
Biosimilars are approved in India for use as alternatives, and studies describe them as significantly improving access. Ask your oncologist which brand is appropriate for you.
Can I keep my breast during treatment?
Often yes, if the tumour is small enough relative to the breast, or if chemotherapy shrinks it first. Your surgeon will discuss this based on your scans and biopsy.
Dr. Aditya Sarin
Consultant, Medical Oncology · Sir Ganga Ram Hospital, New Delhi
MD (General Medicine) · DrNB (Medical Oncology) · ESMO (European) Board Certified
Dr. Aditya Sarin is a medical oncologist who combines precision molecular profiling with evidence-based, compassionate cancer care. Named Young Medical Oncologist of the Year, he treats the full spectrum of solid and blood cancers through a multidisciplinary tumor-board approach at Sir Ganga Ram Hospital.
